SpinaFX Completes Series B Funding Round for Spinal Treatments and Herniated Discs

SpinaFX Medical, an innovator in minimally invasive image-guided spinal care solutions, has completed its Series B funding round, raising its last tranche of CAD $5.3 million. 

Jeff Cambra SpinaFX CEO commented, “This investment, led by a strategic investor, highlights the growing trust in SpinaFX’s groundbreaking technology to address the global burden of back pain. It supports our continued efforts to secure regulatory approvals, driving commercialization, and expanding innovations with our next-generation solution as we seek to advance spinal care. Our mission is to provide an effective solution for the millions of patients suffering from debilitating back pain worldwide.”

The company aims to create minimally invasive, image-guided treatments that will help reduce costs, increase access, and shorten recovery time for patients requiring spinal treatment for contained herniated discs.

SpinaFX’s Triojection is a not-yet-approved therapy that delivers an ozone-oxygen mixture into the disc. Preliminary data from studies indicates the potential of this outpatient procedure to address disc volume and related nerve pressure, pending further clinical validation and regulatory approval.

A recent study was published in the Spine Journal in 2022. The study explored the potential outcomes of the procedure alongside traditional surgical methods and received the ‘Abstract of the Year’ award at the Plenary Presentation of the Society of Interventional Radiology.

“I have been working on intradiscal ozone injection for 18 years. SpinaFX is now dedicated to bringing this innovation to market, working to address the therapeutic gap between failed conservative care and surgery for debilitating back pain,” said Dr. Kieran Murphy, Founder, Chairman and Chief Medical Officer, SpinaFX.